



Bharat Immunologicals & Biologicals Corporation Limited

CIN – L24232UP1989GOI010542 (A Govt. of India Undertaking)

Regd. Office: Vill. Chola, Bulandshahr(UP)-Pin 203203

E-mail-sklalacs@yahoo.co.in

Website – www.bibcol.com Phone (09458096110)

No.BIB/CS/SE/UAFR/Q2/2022-23

Date 17.10.2022

To

The Listing Department
Bombay Stock Exchange
Phiroze jeejeebhoy Tower
25, Dalal Street, Mumbai-400001

Sub: Submission of Un-audited Quarterly Financial Results for the quarter ended September 2022 and Limited Review Report thereon as per the Compliance of LODR 2015

Sir/Madam,

In pursuance of the SEBI LODR, please find attached the Un-audited Quarterly Financial Results for the quarter ended September 2022 and Limited Review Report thereon as per the Compliance of LODR 2015.

Submitted please.

Thanking you,



S. K. Lal
17/10/22

Sandip Kumar Lal
(General Manager/Company Secretary)



Sanjana & Associates
Chartered Accountant

H.NO.-A-1/659-660, 2nd
Floor, Sector-6, Rohini,
Delhi-110085

Limited Review Report

In case of M/s Bharat Immunologicals and Biologicals Corporation Limited

Review Report to the Shareholders of M/s Bharat Immunologicals and Biologicals Corporation Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s Bharat Immunologicals and Biologicals Corporation Limited** for the period of 1st July, 2022 to 30th September, 2022. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Sanjana & Associates
Chartered Accountant
FRN:037966N

Date:- 11-10-2022
Place:- Delhi
UDIN : 22559855AZFKWZ4855



CA Sanjana Garg
M.No.- 559855

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LIMITED

CIN:- L24232UP1989GOI010542

Part I

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30-09-2022

Selected Information for the Period Ended 30-09-2022

(INR in Lakh)

S. No	Particulars	3 Months Ended on 30-09-2022	Preceding 3 Months Ended on 30-06-2022	Corresponding 3 Months Ended in the previous year 30-09-2021	Half Year Ended on 30- 09-2022	Previous Year Ended as on 31- 03-2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	INCOME					
	a) Income from Operations	2,647.96	1,047.92	2,470.16	3,695.88	7,838.80
	b) Other Income	31.95	14.36	21.73	46.31	110.23
	Total Revenue (1)	2,679.91	1,062.28	2,491.89	3,742.19	7,949.03
2	EXPENDITURE					
	a) Cost of Material Consumed	10.61	2,641.63	1,420.29	2,652.24	5,918.51
	b) Purchase of Stock in Trade	-	-	-	-	-
	c) Change in Inventory of Finished Goods, Work in Progress and Stock in Trade	2,427.29	-1,832.73	775.60	594.56	44.46
	d) Employees Benefits	394.98	395.33	305.44	790.31	1,384.91
	e) Finance Cost	174.22	158.04	122.78	332.26	559.17
	f) Depreciations and Amortization Expense	3.65	3.65	5.75	7.30	21.27
	g) Other Expense	65.08	326.73	318.03	391.81	989.46
	Total Expense (2)	3,075.83	1,692.66	2,947.89	4,768.49	8,917.77
3	Profit/ (Loss) before exceptional items (1-2)	-395.92	-630.37	-456.00	-1,026.29	-968.74
4	Tax Expense					
	a) Current Tax	-	-	-	-	-
	b) Deferred Tax	-87.60	-130.71	480.09	-218.31	-93.38
5	Profit/ (Loss) from continuing Operations (3-4)	-308.31	-499.66	-936.09	-807.97	-875.36
6	Other Comprehensive Income/(Loss) (Net of Taxes)	-	-	-	-	-
7	Total Comprehensive Income/ (Loss) for the period (5+6)	-308.31	-499.66	-936.09	-807.97	-875.36
8	Paid Up Equity Share Capital (Face Value of INR 10/- each)	4,318.00	4,318.00	4,318.00	4,318.00	4,318.00
9	Earning Per Share (of INR 10/- each) not annualized					
	a) Basic	-0.71	-1.16	-2.17	-1.87	-2.03
	b) Diluted	-0.71	-1.16	-2.17	-1.87	-2.03

Note:- Refer our Note Separately

S. lip.

Part II

Selected Information for the Period Ended 30-09-2022

S. No	Particulars	3 Months Ended on 30-09-2022	Preceding 3 Months Ended on 30-06-2022	Corresponding 3 Months Ended in the previous year 30-09-2021	Half Year Ended on 30-09-2022	Previous Year Ended as on 31-03-2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A1	PARTICULARS OF SHAREHOLDING					
	Public shareholding					
	- Number of Shares	17,594,000.00	17,594,000.00	17,594,000.00	17,594,000.00	17,594,000.00
	- Percentage of shareholding	40.75	40.75	40.75	40.75	40.75
A2	Promoters and Promoters Group shareholding					
	a) Pledged/ Encumbered					
	- Number of Shares	-	-	-	-	-
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shareholding (as a% of the total share capital of the company)	-	-	-	-	-
	b) Non - encumbered					
	- Number of Shares	25,586,000.00	25,586,000.00	25,586,000.00	25,586,000.00	25,586,000.00
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of shareholding (as a% of the total share capital of the company)	59.25	59.25	59.25	59.25	59.25
B	Particulars	3 Months ended (30-09-2022)				
	INVESTOR COMPLAINTS					
	Pending at the beginning of the quarter	0				
	Received during the quarter	0				
	Disposed of during the quarter	0				
	Remaining unresolved at the end of the quarter	0				

S. S. P.

Segment Reporting for the Period Ended 30-09-2022

(INR in Lakhs)

S. No	Particulars	3 Months Ended on 30-09-2022	Preceding 3 Months Ended on 30-06-2022	Corresponding 3 Months Ended in the previous year 30-09-2021	Half Year Ended on 30-09-2022	Previous Year Ended as on 31-03-2022
1	SEGMENT REVENUE					
	Oral Polio Vaccine	2,647.96	1,047.90	2,469.04	3,695.86	7,835.26
	Zinc Dispersible Tablets	-	-	-	-	-
	BIB Sweet Tablets	-	-	-	-	0.02
	BIBSANIT	-	0.02	1.12	0.02	3.52
	Less: Inter segment revenue	-	-	-	-	-
	Net Sales/ Income from operations	2,647.96	1,047.92	2,470.16	3,695.88	7,838.80
2	SEGMENT RESULTS (Profit Before Tax)					
	Oral Polio Vaccine	-308.31	-499.66	-936.09	-807.97	-875.16
	Zinc Dispersible Tablets	-	-	-0.03	-	-
	BIB Sweet Tablets	-	-	-	-	-
	BIBSANIT	-	-	-0.46	-	-0.20
	Less: Unallocable expenditure net off un allocable Income	-	-	-	-	-
	Total Profit before Tax	-308.31	-499.66	-456.00	-807.97	-875.36
3	CAPITAL EMPLOYED (Segment Assets less Liabilities)					
	Oral Polio Vaccine	19,144.51	19,144.51	12,604.12	19,144.51	19,144.51
	Zinc Dispersible Tablets	-226.10	-226.10	7.34	-226.10	-226.10
	BIB Sweet Tablets	-	-	-	-	-
	BIBSANIT	-	-	78.00	-	-
	Others	1,109.86	1,109.86	39.48	1,109.86	1,109.86
	Total Capital employed	20,028.27	20,028.27	12,728.94	20,028.27	20,028.27

Sat.

1. The above Un-Audited results for the Quarter ended 30th September, 2022 have been review by the Audit Committee and were taken on record by the Board of Directors in their meeting held on October 17, 2022.
2. Valuation of Closing Stock has been done on the basis of Net realizable value.
3. In quarters, depreciation has been charged on the basis of Companies Act 2013.
4. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rule 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
5. The format for unaudited quarterly results as prescribed in SEBI's Circular dated November 30, 2015 has been modified to comply with requirements of SEBI's Circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
6. The statement does include Ind AS compliant results for the preceding quarter and previous year ended 30th September, 2021.
7. Segment information as per Ind AS 108 has been given above as Segment Reporting. The Company is currently engaged in production of Oral Polio Vaccine, Zinc Dispersible Tablets and Sweetener.
8. The Ind As complaint corresponding figures in the previous year have been reviewed / audited. However, the company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
9. The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS as given below: For Table, kindly refer Corporate Announcements on www.bseindia.com.
10. Previous year/quarter figures have been regrouped/re-arranged wherever necessary, to make it comparable.

Place:-Delhi

Date :- 17.10.2022




(Chaitanya Murti)
Managing Director

Bharat Immunologicals and Biologicals Corporation Limited
Statement of Assets & Liabilities as on 30th September 2022

Particulars		Note No.	As at 30th September 2022	As at 31st March 2022
A	ASSETS			
1	Non-current assets			
	(a) Property, Plant and Equipment	4	8,400.78	8,408.08
	(b) Capital work-in-progress		3,190.00	3,190.00
	(c) Financial Assets	5	1,231.63	906.33
	(d) Other non-current assets	6	44.84	44.84
	(e) Non Current Tax Assets (Net)	7	72.42	78.06
	(f) Deferred tax assets (net)	8	2,342.38	2,102.63
			15,282.05	14,729.94
2	Current assets			
	(a) Inventories			-
	(b) Financial Assets	9	823.12	3,624.97
	(i) Investments			-
	(ii) Trade receivables	10	2,777.70	113.29
	(iii) Cash and cash equivalents	11	17.67	464.30
	(iii) Bank balances other than (ii) above	12	796.80	836.65
	(c) Other current assets	13	1,400.45	1,503.66
			5,815.75	6,542.88
	Total		21,091.69	21,272.86
B	EQUITY AND LIABILITIES			
1	Equity			
	(a) Equity Share capital	14	4,318.00	4,318.00
	(b) Other Equity	15	5,409.34	6,217.32
			9,727.34	10,535.32
2	Non-current liabilities			
	(a) Deferred Grant			-
	(b) Long Term Provisions	16	-	
		17	659.15	611.15
			659.15	611.15
3	Current liabilities			
	(a) Financial Liabilities			-
	(i) Borrowings	18	8,014.07	7,788.50
	(ii) Trade payables	19	655.61	86.94
	(iii) Other Financial Liabilities	20	118.80	118.75
	(b) Deferred Grant	16	-	-
	(c) Short Term Provisions	21	667.99	535.18
	(d) Other Current liabilities	22	1,245.83	1,597.03
			10,702.30	10,126.39
	Total		21,091.69	21,272.86

S. S. P.

Cash flow statement, indirect		
Particulars		6 months ended (30-09-2022)
A	Date of start of reporting period	01-04-2022
B	Date of end of reporting period	30-09-2022
C	Whether results are audited or unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
	Statement of cash flows	
	Whether cash flow statement is applicable on company	Yes
	Cash flows from used in operating activities	
	Profit before tax	
	Adjustments for reconcile profit (loss)	-419.39
	Adjustments for finance costs	
	Adjustments for decrease (increase) in inventories	174.220
	Adjustments for decrease (increase) in trade receivables, current	2801.860
	Adjustments for decrease (increase) in trade receivables, non-current	-2664.410
	Adjustments for decrease (increase) in other current assets	0.000
	Adjustments for decrease (increase) in other non-current assets	126.690
	Adjustments for other financial assets, non-current	0.000
	Adjustments for other financial assets, current	0.000
	Adjustments for other bank balances	-325.300
	Adjustments for increase (decrease) in trade payables, current	39.850
	Adjustments for increase (decrease) in trade payables, non-current	568.680
	Adjustments for increase (decrease) in other current liabilities	0.000
	Adjustments for increase (decrease) in other non-current liabilities	19.820
	Adjustments for depreciation and amortization expense	0.000
	Adjustments for impairment loss reversal of impairment loss recognized in profit or loss	3.650
	Adjustments for provisions, current	0.000
	Adjustments for provisions, non-current	-180.810
	Adjustments for other financial liabilities, current	0.000
	Adjustments for other financial liabilities, non-current	48.000
	Adjustments for unrealized foreign exchange losses gains	0.000
	Adjustments for dividend income	0.000
	Adjustments for interest income	0.000
	Adjustments for share-based payments	0.000
	Adjustments for fair value losses (gains)	0.000
	Adjustments for undistributed profits of associates	0.000
	Other adjustments for which cash effects are investing or financing cash flow	0.000
	Other adjustments to reconcile profit (loss)	0.000
	Other adjustments for non-cash items	0.000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0.000
	Total adjustments for reconcile profit (loss)	612.250
	Net cash flows from (used in) operations	192.860
	Dividends received	
	Interest paid	
	Interest received	0.000
	Income taxes paid (refund)	0.000
	Other inflows (outflows) of cash	0.000
	Net cash flows from (used in) operating activities	192.860
	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0.000
	Cash flows used in obtaining control of subsidiaries or other businesses	0.000
	Other cash receipts from sales of equity or debt instruments of other entities	0.000
	Other cash payments to acquire equity or debt instruments of other entities	0.000
	Other cash receipts from sales of interests in joint ventures	0.000
	Other cash payments to acquire interests in joint ventures	0.000
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0.000
	Cash payment for investment in partnership firm or association of persons or limited liability	0.000

S.H.

partnerships	
Proceeds from sales of property, plant and equipment	0.000
Purchase of property, plant and equipment	0.000
Proceeds from sales of investment property	0.000
Purchase of investment property	0.000
Proceeds from sales of intangible assets	0.000
Purchase of intangible assets	0.000
Proceeds from sales of intangible assets under development	0.000
Purchase of intangible assets under development	0.000
Proceeds from sales of goodwill	0.000
Purchase of goodwill	0.000
Proceeds from biological assets other than bearer plants	0.000
Purchase of biological assets other than bearer plants	0.000
Proceeds from government grants	0.000
Proceeds from sales of other long-term assets	0.000
Purchase of other long-term assets	0.000
Cash advances and loans made to other parties	0.000
Cash receipts from repayment of advances and loans made to other parties	0.000
Cash payments for future contracts, forward contracts, option contracts and swap contracts	0.000
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0.000
Dividends received	0.000
Interest received	0.000
Income taxes paid (refund)	0.000
Other inflows (outflows) of cash	0.000
Net cash flows from (used in) investing activities	0.000
Cash flows from used in financing activities	
Proceeds from changes in ownership interests in subsidiaries	0.000
Payments from changes in ownership interests in subsidiaries	0.000
Proceeds from issuing shares	0.000
Proceeds from issuing other equity instruments	0.000
Payments to acquire or redeem entity's shares	0.000
Payments of other equity instruments	0.000
Proceeds from exercise of stock options	0.000
Proceeds from issuing debentures notes bonds etc	0.000
Proceeds from borrowings	0.000
Repayments of borrowings	0.000
Payments of finance lease liabilities	0.000
Payments of lease liabilities	0.000
Dividends paid	0.000
Interest paid	0.000
Income taxes paid (refund)	174.220
Other inflows (outflows) of cash	0.000
Net cash flows from (used in) financing activities	-465.270
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	-639.490
Effect of exchange rate changes on cash and cash equivalents	-446.630
Effect of exchange rate changes on cash and cash equivalents	
Net increase (decrease) in cash and cash equivalents	-446.630
Cash and cash equivalents cash flow statement at beginning of period	464.300
Cash and cash equivalents cash flow statement at end of period	17.67

Slip